Skip To Main Content
C. Iribarren on Muck Rack

C. Iribarren

As seen in: Wiley Online Library
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with C.

Contact C., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Cardiovascular Outcomes With Dupilumab Versus Omalizumab in Severe Asthma

|
By Po-Cheng Shih, Chun-Ting Lin, C. Iribarren
| Wiley Online Library Verified
To the Editor, Severe asthma is associated with increased cardiovascular morbidity, but comparative cardiovascular safety data across biologic agents remain limited [1, 2]. We therefore emulated a target trial comparing major adverse cardiovascular events among patients initiating dupilumab or omalizumab. We used the TriNetX U.S. Collaborative Network from January 1, 2019, to December 31, 2025.
Open in Who Shared Issue with article?
See all 1 articles